GlassScriptPhysician profile
Christine D Albrecht
NPI 1932104486
$4,583.75
in general payments reported to CMS, 2019-2025
31 companies · $650 in 2025
The $650 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $662 · 2021: $578 · 2022: $542 · 2023: $815 · 2024: $590 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.49 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $634.10 | 2022-2025 | |
| Abbvie INC. | $620.92 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $467.70 | 2023-2025 | Myfembree |
| Amgen INC. | $403.69 | 2019-2025 | Evenity, Prolia, Prolia |
| Therapeuticsmd, INC. | $330.15 | 2019-2022 | |
| Astellas Pharma US INC | $282.18 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $257.77 | 2019-2025 | Wegovy, Saxenda |
| Bausch Health US, LLC | $197.30 | 2019-2022 | |
| Millicent US INC | $194.33 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $173.31 | 2019-2024 | |
| Avion Pharmaceuticals | $103.25 | 2021-2023 | Balcoltra |
| Lupin INC. | $95.50 | 2019-2020 | |
| Exeltis, USA INC. | $89.63 | 2024-2025 | Slynd |
| Merck Sharp & Dohme LLC | $79.40 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $78.96 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $76.22 | 2021-2022 | |
| Hologic Sales and Service, LLC | $65.70 | 2022-2025 | Omni Hysteroscope, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Lilly USA, LLC | $47.88 | 2020-2025 | Zepbound |
| Ascend Therapeutics US, LLC | $43.22 | 2023 | |
| Duchesnay USA Incorporated | $40.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.07 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $38.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.33 | 2021 | |
| Dysis Medical, INC. | $32.56 | 2022 | |
| Currax Pharmaceuticals LLC | $32.17 | 2021-2022 | |
| Exact Sciences Corporation | $30.93 | 2025 | The Cologuard Plus Collection Kit |
| Evofem Biosciences, INC. | $30.03 | 2020-2021 | |
| Alfasigma USA, INC. | $18.43 | 2022 | |
| Coloplast Corp | $17.72 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $14.89 | 2019 | |
| Coopersurgical, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.